Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia
NCT07653672
Summary
The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is To develop and validate a clinical-biological score (VISCOTHEM score) incorporating viscoelastometric tests parameters; based on an association study, and to establish a threshold that enables the prediction of the immediate risk of bleeding in haematology patients with severe thrombocytopenia (\<20 G/L); with a view to selecting a population with a residual risk of bleeding of zero (NPV ≥ 95%, to achieve a residual probability of bleeding \< 5%). The score may incorporate variables identified in the literature as having a plausible causal relationship with the occurrence of bleeding (14,15), as well as viscoelastometric tests parameters, conventional haemostasis parameters and relevant clinical parameters. . Participants will undergo an additional blood sample to standard care. The total volume of blood drawn will be 21.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen, urea, creatinin, albumin.
Eligibility
Inclusion Criteria: * Adult patients; * Who have been informed about the study and have freely given their informed consent to participate in the study; * With a malignant haematological disorder or bone marrow failure, whether treated or untreated and at any stage of treatment; * With central thrombocytopenia strictly below 20 G/L in a blood sample taken less than 72 hours ago and not having received a transfusion since; * Admitted to a haematology day unit or inpatient ward, or being followed up at a haematology outpatient clinic; * With or without active bleeding; * Affiliated with or covered by a social security scheme. Exclusion Criteria: * Patients who have received at least one of the following treatments: * Antiplatelet agents within 7 days prior to enrolment, * Vitamin K antagonists within 7 days prior to enrolment, * Direct oral anticoagulants within 72 hours prior to enrolment, * Low molecular weight heparin within 24 hours prior to inclusion, * Unfractionated heparin within 6 hours prior to inclusion, * Bruton's tyrosine kinase inhibitor (ibrutinib, zanubrutinib or acalabrutinib) within 72 hours prior to inclusion; * Patients with a history of thrombopathy; * Patients with a history of haemostatic disorders carrying a risk of haemorrhage or thrombosis; * Thrombocytopenia associated with immune thrombocytopenic purpura or disseminated intravascular coagulation; * Patients already enrolled in the study; * Pregnant or breastfeeding women; * Patients under guardianship or curatorship; * Patients who do not understand French; * Patients under judicial protection.
Conditions5
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07653672